Treximet (Sumatriptan Succ/Naproxen Sod) Patent Expiration, LOE Window & CMS Spending

Treximet (Sumatriptan Succ/Naproxen Sod) by Azurity: FDA Orange Book LOE 2026-04-02, 3 AB generics, $749K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAzurity
FDA Application & PathwayN021926 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-04-02
Orange Book Patents (*PED Extensions)2 patents (1 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$749K
2024 Medicare Part D Spend$749K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel